Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 11 of 15
Mar 19, 2026The 2026 labor market within the U.S. life sciences sector reflects a dynamic workforce environment where job mobility has become a critical strategy for salary advancement. A new BioSpace report highlights the substantial financial benefits for those switching employers amid ongoing economic pressures and industry recalibration.
Mar 18, 2026The pharmaceutical sector is currently characterized by a cautious approach towards deals, with a preference for mid-sized transactions. Industry experts argue that, given the substantial capital reserves, there may be a strategic imperative to consider larger scale mergers and acquisitions to strengthen competitive positioning and innovation capacity.
Mar 10, 2026The recent funding round led by Breakout Ventures highlights growing investor interest in artificial intelligence applications within biotechnology. This fund focuses on early-stage companies, a segment seeing increasing investor interest despite a broader market trend favoring derisked assets. The infusion of capital reflects confidence in AI-driven drug discovery's transformative potential.
Mar 5, 2026With the raising of substantial capital, Science Corp. is poised to bring forward a transformative medical device aimed at restoring vision. This funding milestone underscores strong investor confidence as the company awaits the FDA's critical decision on the PRIMA retinal implant.
Mar 5, 2026The breakdown in contract negotiations between Mount Sinai and Anthem Blue Cross Blue Shield highlights the broader challenges faced by payers and providers amid escalating healthcare costs and administrative complexities. This separation further underscores the critical need for innovative strategies to manage and control healthcare expenses effectively.
Mar 4, 2026The latest infusion of venture capital into biotech reflects growing interest in novel therapies for inflammatory bowel diseases. Following promising Phase 2b results demonstrating sustained clinical remission, Teva’s project has attracted major backing to support further clinical development and potential market entry.
Mar 4, 2026The recent Series D funding round for Grow Therapy underscores a growing industry focus on scalable mental health solutions integrated with employer and health system networks. This capital infusion aims to broaden Grow Therapy's footprint in connecting patients to necessary mental health care resources, thereby addressing increasing demand.
Mar 3, 2026In the rapidly evolving healthcare AI sector, investors are shifting their focus towards tangible returns amid heightened market scrutiny. This post explores the insights from four prominent venture capitalists on what matters most for AI startups to succeed in today's environment.
Mar 3, 2026The health tech sector continues its upward trajectory with robust funding rounds reported in February 2026. This article highlights five notable investments that reflect the evolving landscape where technology is reshaping healthcare delivery and patient management.
Mar 1, 2026In an effort to address the burden of rising prescription drug costs, GoodRx rolls out a program that allows employers to subsidize brand medication prices directly. This strategy aims to enhance medication affordability for employees while maintaining the status quo of employer health insurance plans.
Feb 27, 2026Founded by Flagship Pioneering, Generate Biomedicines aims to revolutionize severe asthma treatment with a novel therapeutic designed using advanced AI and machine learning. This new drug promises less frequent injections compared to existing blockbuster therapies developed by leading pharmaceutical companies.
Feb 27, 2026At the recent JPM26 conference, BioSpace captured the pulse of the healthcare industry, examining key trends in biotech innovation, regulatory changes, and investment flows. This detailed report examines the implications for investors, companies, and policy makers navigating a rapidly evolving landscape.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.